Ukraine has procured 12,000 doses of the drug PLX-R18, intended for treating radiation sickness (acute radiation syndrome), from the Israeli biotech firm Pluri. This acquisition is made in preparation for a potential nuclear threat.

This was announced by Israel's ambassador to Ukraine, Michael Brodsky, on Telegram, referencing The Times of Israel.

Reserve for nuclear safety: Ukraine has obtained PLX-R18 medication

The ambassador quoted the Israeli publication, stating that “the Israeli company Pluri signed a contract with a Ukrainian cord blood bank for the supply of PLX-R18 medication.” This drug aids in the recovery of platelets as well as red and white blood cells damaged by radiation exposure.

Overall, Ukraine will receive enough doses to treat 6,000 individuals. The purchased medication will be stored as a reserve in case of a nuclear threat. If needed, it will be promptly dispatched to hospitals across the country to assist the affected.

In March, Russian forces reportedly utilized chemical weapons against the Armed Forces of Ukraine nearly 770 times.

Earlier, the General Staff of the Armed Forces of Ukraine reported 767 instances of Russian military employing munitions containing hazardous chemical substances against Ukrainian Defense Forces throughout March 2025.

Since February 2023, when such attacks became systematic, 7,730 similar incidents have been recorded.

As of the beginning of March, since the full-scale invasion, Russian troops have used munitions with toxic chemical compounds over 6,900 times.

In March 2024, the Ukrainian delegation at the OSCE urged the international community to respond beyond mere political condemnation regarding Russia's use of chemical weapons against Ukrainian defenders.